most frequently 7 to 10 days. The possibility of a rebound effect after withdrawal of nonsteroidal antiinflammatory drugs (NSAIDs) was raised in previous studies, but the mechanism remains poorly understood. 14 For example, Sibon and Orgogozo 3 reported that 4.5% of their patients with ischemic stroke reported discontinuation of antiplatelet drugs within the previous month, and 85% of them were taking aspirin. The stroke occurred 7.4 ± 1.26 days after discontinuation of the treatment. Fisher et al 6 reported a 1.52-fold risk of acute myocardial infarction (95% confidence interval, 1.33-1.74) in patients who stopped NSAIDs between 1 and 29 days before testing compared with nonusers. Ferrari et al 7 support the hypothesis that aspirin withdrawal may represent a real risk for the occurrence of a new coronary event. In a series of 1236 patients hospitalized for acute coronary syndrome, 4.3% of the events but 13.3% of the recurrences were present 10 ± 1.9 days after aspirin withdrawal. Similar observations were reported by Collet et al 9 
in a series
A spirin remains the most widely used drug for prevention of vascular events. Taken alone or in association with clopidogrel, it has shown a positive effect in acute myocardial infarction patients or for the prevention of atherothrombotic events. 1, 2 Recent observational epidemiologic evidence has raised the concern that aspirin withdrawal for treatment noncompliance, surgery, or side effects can carry an increased thrombotic risk. This risk appears to be increased for ischemic stroke, 3-5 cardiovascular problems, [6] [7] [8] [9] [10] [11] [12] and acute lower limb ischemia. 13 The delay to the thrombotic event was between 7 to 30 days in most reports and Aspirin remains the most widely used drug for prevention of vascular events. Recent observational epidemiological evidence has raised the concern that aspirin withdrawal for treatment noncompliance, surgery, or side effects can carry an increased thrombotic risk. The delay to the thrombotic event was between 7 to 30 days in most reports and most frequently 7 to 10 days. The mechanism underlying this effect remains poorly understood. Using an in vivo model of laser-induced thrombosis, aspirin injected in 1 single dose of 100 mg/kg body weight has also shown a prothrombotic activity in the rat 8 to 10 days after injection in the normal rat. The hypothesis was made that minimal concentrations of aspirin or ultra-low dose aspirin (ULDA) could induce this effect. ULDA showed prothrombotic properties in the same model of induced thrombosis that were very similar to those described after aspirin withdrawal, but the effect was observed only 1 hour after aspirin administration. This prothrombotic effect of ULDA is very similar to the effect observed after COX 2 selective inhibition with NS 398. The administration of both the selective COX 2 inhibitor and ULDA did not produce further changes. In conclusion, the prothrombotic effects described in recent observational studies are likely produced by a direct effect of aspirin, whose putative mechanism involving COX 2 inhibition remains poorly understood. Keywords: aspirin withdrawal; thrombosis; COX 1 inhibition; COX 2 inhibition of 1358 patients. Burger et al 8 and Biondi-Zoccai et al 11 in 2 meta-analyses of 49 590 and 50 279 patients, respectively, suggested that aspirin withdrawal or nonadherence preceded 10.2% of acute coronary syndromes and was associated with a threefold higher risk of major cardiac events (odds ratio = 3.14 [1.75-5.61]; P = .0001). The time interval in days between discontinuation and the events was 14.3 ± 11.3 for stroke, 8.5 ± 11.3 for acute coronary syndromes, and 25.8 ± 18.1 for acute peripheral syndromes. 8 The main mechanism of the antithrombotic effect of aspirin is a definitive inhibition of COX 1 by acetylation that decreases the production of TXA 2 in the platelets and the production of PGI 2 in the endothelial cells. As platelets lack a cell nucleus and cannot synthesize more COX 1, this inhibition remains for the lifespan of the platelets and decreases with the progressive generation of new platelets. In the endothelial cells, new COX 1 is synthesized and PGI 2 production can be restarted. COX 2, an inducible form of COX, which is present in the endothelium but not mainly in the platelets, is also able to increase PGI 2 production. As a result of these effects, the normal balance between antithrombotic endothelial PGI 2 and prothrombotic platelet TXA 2 is switched to a new state in which the antithrombotic effect of endothelial PGI 2 prevails. Aspirin half-life is 13 to 19 minutes and is metabolized to salicylate, which has a half-life of 3.5 to 4.5 hours. The delay of several days observed between aspirin withdrawal and the thrombotic event raises the possibility that aspirin might have some long-lasting prothrombotic effect. The hypothesis of a rebound effect and different aspects of the prothrombotic effects of aspirin have been studied in our laboratory.
Experimental Models

Model of Laser-Induced Thrombosis
To observe in vivo the intimate nature of changes in thrombosis pathophysiology, endothelial cells, subendothelial collagen, and platelets should be present in the most unmodified manner. In 1992, our laboratory used a laser-induced thrombosis model in mesenteric vessels. The power was set to 120 mW and the exposure to 1/15 second. To validate this model, higher doses of aspirin were initially tested (50, 100, and 200 mg/kg rat weight). The parameters used were the number of shots required to start embolization, the number of emboli observed after the laser shot and the duration in minutes of the resulting embolization. The 3 doses of aspirin increased the number of laser injuries required to start embolization in a dose-dependent manner, and the number of emboli and the duration of embolization were decreased. 15 
Induced Hemorrhagic Time (IHT)
An experimental model of hemorrhage was performed 10 minutes before laser-induced thrombosis. The rat tail was immersed for 5 minutes at 37°C and sectioned 6 mm from the extremity. IHT expressed in seconds corresponded to the time between tail sectioning and the end of bleeding.
Drugs Tested
Various very low doses of aspirin as well as aspirin and salicylate at 100 mg/kg were tested with the laser thrombosis model and also by IHT in the rat tail. Aspirin solutions were purchased from Boiron Laboratories (Sainte-Foy-Les-Lyons, France) and were prepared as follows: 1 g of pure, finely powdered aspirin was suspended in 99 mL of alcohol (70°). After being vigorously shaken, 1 mL of this dilution was then mixed with 99 mL of distilled water and vigorously shaken. The last process was repeated several times until the desired aspirin concentration was reached. All products were injected in a final volume of 1 mL/kg body weight. The ultra low dose aspirin (ULDA) used was an actively prothrombotic dose prepared as described as above until the final concentration of 334 × 10 (-11) mol/mL was reached. 16 
Effects in Time of One Antithrombotic Dose of Aspirin
Frequently, the thrombotic events observed several days after aspirin withdrawal are considered a rebound effect or a return to the baseline of a patient with an already increased risk. The half-life of a low dose of aspirin is approximately 13 to 19 minutes and that of salicylate 3.5 to 4.5 hours. Nevertheless, as the acetylation of COX 1 produced by aspirin is definitive, the effect remains for several days until new platelets are generated. The effect in time of 1 single dose of aspirin was studied with the injection of 1 antithrombotic dose of aspirin (100 mg/kg body weight) and performing laser-induced thrombosis 2, 4, 6, 8, 10, 12, 14, and 16 days after the injection. 17 Groups are shown in Table 1 . There was a potent antithrombotic effect 2 days after injection, decreasing the number of emboli and the duration of embolization (Figures 1 and 2) . Nevertheless, thrombi formation was increased at days 8 and 10, expressing in the normal rat results similar to the observational epidemiological data described above. This experiment clearly demonstrates the antithrombotic effect of aspirin 2 days after injection and showed that a prothrombotic state can be observed several days after a single aspirin dose in a normal rat for a given period of time. A rebound effect could not be ruled out by this experiment, but this effect is obviously also observed in the normal rat.
Dose-Dependent Effects of Aspirin
The effects of different doses of aspirin, including very low decreasing doses of aspirin, have also been tested in our laboratory. The doses studied were saline control, salicylate 100 mg/kg, aspirin 100 mg/kg, and decreasing doses of aspirin covering very extended values. The detailed description of the groups and doses is given in Table 2 . The methods used included laser-induced thrombosis and IHT as described above, and the results are shown in Table 3 and Figure 3 . Aspirin 100 mg/kg body weight showed an antithrombotic effect with a decreased formation of emboli and duration of embolization and a prolonged IHT. Importantly, the lowest doses of aspirin (ULDA) showed a prothrombotic effect only in the laser study, whereas IHT was unchanged. Conversely, 100 mg/kg and 1 mg/kg of aspirin produced a clear Aspirin 100 mg/kg T 0 + 6 5
Aspirin 100 mg/kg T 0 + 8 6
Aspirin 100 mg/kg T 0 + 10 7
Aspirin 100 mg/kg T 0 + 12 8
Aspirin 100 mg/kg T 0 + 14 9
Aspirin 100 mg/kg T 0 + 16 a Experimental groups and tested doses (n = 7 rats/group). T 0 + days: number of days after injection. prolongation of IHT, indicating not an opposite mechanism but likely a different one. The study showed that it was the very low dose of aspirin more than a rebound effect that induced this prothrombotic effect.
Study of COX Selective Inhibition in Association With Aspirin
The mechanism of this effect is not clearly understood. As COX inhibition is the main mechanism of the effect of aspirin, COX inhibitors were used to try to understand the action of ULDA. COX 1 is a constitutive enzyme responsible for the production of TXA 2 in platelets. For the above-explained reasons, COX 1 inhibition exerts an antithrombotic influence. COX 2, although inducible, has been claimed to be constitutive in many tissues, including the vascular endothelium. The chronic selective inhibition of COX 2 has been blamed for being prothrombotic and causing serious vascular complications such as myocardial infarction and stroke. 18 We made the hypothesis that the mechanism of the prothrombotic effect that we observed with ULDA could be related to the increased thrombotic risk observed after aspirin withdrawal and also to COX 2 selective inhibition. Therefore, COX selective inhibitors were administered to observe whether they were capable of modifying the prothrombotic effect of ULDA. In this study, SC 560 was used as selective inhibitor of COX 1 and NS 398 as selective inhibitor of COX 2, both administered per os at a dose of 10 mg/kg in a suspension of CMC at 0.5% w/v. Wistar rats were separated into 3 pairs of groups. Each pair was respectively treated with placebo (CMC solution), COX 1 inhibitor, or COX 2 inhibitor. Within each pair, 1 group received ULDA and the other a placebo injection (distilled water according to the same procedures as ULDA but without the aspirin). The parameters studied were laser-induced thrombosis to evaluate platelet-endothelial cell interactions in the microvasculature and IHT as described above. The results showed an antithrombotic effect of COX 1 inhibition, decreasing the number of emboli and the duration of embolization and prolonging IHT. Adding ULDA to the group with COX 1 inhibitor produced a normalization of these parameters. When selective inhibition of COX 2 was evaluated, the effect of NS 398 was slightly prothrombotic in the microvasculature, increasing the duration of embolization. The addition of ULDA did not produce further changes in the prothrombotic action of NS 398 but IHT was slightly shortened.
The conclusions were that the administration of ULDA or NS 398 had prothrombotic effects and that the previous dose of NS 398 prevented posterior increases in induced thrombus production with ULDA administration. Laser-induced thrombosis seemed to be a more sensitive technique to investigate this process than IHT. Therefore, ULDA could share a mechanism with the COX 2 selective inhibitor. 19
Discussion
Recent epidemiological evidence suggests that the withdrawal of aspirin because of noncompliance or for surgical interventions can carry an increased risk of thrombotic events. This increased risk is observed within the first month, and mostly within the first 2 weeks. The main result of this increased risk could be ischemic stroke, myocardial infarction, or lower limb ischemia. The mechanism of this effect is not well understood and is often interpreted as a rebound effect in patients with an increased risk of ischemic events. The delay between these events and aspirin withdrawal was almost reproduced by us in the normal rat, with a single injection of aspirin at the dose of 100 mg/kg on days 8 and 10 after administration. It is not clear whether this effect is caused by aspirin itself or by a rebound effect. Nevertheless, these data emphasize the presence of the same effect in the normal rat and not in a subject clearly predisposed to an ischemic event.
The effects observed after ULDA administration rule out the speculation about a rebound effect. A minimal dose of injected aspirin produces a clear prothrombotic effect, increasing the number of emboli and duration of embolization after a laserinduced endothelial lesion, an effect achieved only 1 hour after the administration. This effect seemed to be directly induced by the ULDA injection and not by a rebound effect. IHT was not modified by the lowest doses of aspirin, showing that the laserinduced thrombosis model is more sensitive for testing the interaction between platelets and endothelial cells in the mesenteric microcirculation and for investigating the prothrombotic effect of ULDA.
The inhibition of COX 2 mARN and protein level by low concentrations of aspirin or salicylate in isolated endothelial cells has been described in previous publications and reviewed by Wu. 20 Higher concentrations of aspirin were here described as enhancers of COX 2 protein level. This observation led us to postulate that very low doses of aspirin could induce a prothrombotic action, in addition to its inhibiting activity on platelet COX 1. Selective inhibition of COX 1 induced an antithrombotic effect, decreasing the number of emboli and the duration of embolization and prolonging IHT. The simultaneous administration with ULDA resulted in a normalizing effect of ULDA on the effect of the inhibitor. The evaluation of COX 2 inhibition showed similar effects on thrombus production in microcirculation to that of ULDA, as both increased the duration of embolization. Moreover, the successive administration of COX 2 selective inhibitor and ULDA did not induce a further effect on thrombus induction, thus suggesting a possible common pathway for the effect.
Conclusion
Growing epidemiological evidence suggests an increased thrombotic risk after aspirin withdrawal or for noncompliance, with the first 2 weeks being the most critical. To reproduce this effect in an animal model, the administration in a normal rat of 1 single antithrombotic dose of aspirin triggered a prothrombotic effect observed on days 8 and 10 after injection. The administration of ULDA had a similar prothrombotic effect only 1 hour after injection. This finding suggests a likely direct effect of aspirin administration and not only a rebound effect in patients predisposed to thrombotic events. COX 2 selective inhibition produces an effect similar to that observed with ULDA while the simultaneous administration of both produces no changes. This prothrombotic effect is not likely to be a rebound effect and is possibly due to COX 2 inhibition, although its mechanism is not well understood.
